Researchers are collecting blood samples to learn more about the antigens that cause certain T cells to trigger intestinal damage in celiac disease patients. Complete a 30-minute study from home & be compensated $50 for your time.
Continue ReadingImmunsanT announces end of its global Phase 2 clinical trial for its Nexvax2 drug candidate. Early results indicate gluten-exposure protection similar to placebo.
Continue ReadingIf you have celiac disease and currently have kidney stones, or have had kidney stones in the past, you may be eligible for a clinical research study!
Continue ReadingIf you have celiac disease and currently have kidney stones, or have had kidney stones in the past, you may be eligible for a clinical research study!
Continue ReadingAttention: Volunteers who have prior confirmation of celiac disease from blood work or a biopsy. If you meet the following criteria, you may qualify for a clinical research study of an investigational drug. Medical insurance is not necessary.
Continue ReadingThe CeliacShield Study is being conducted to assess the investigational drug latiglutenase and its ability to protect the small intestine of celiac disease patients from gluten exposure.
Continue ReadingCeliac Disease Foundation is pleased to announce the March 30-31, 2015, U.S. Food and Drug Administration (FDA) public workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3). This scientific meeting will address endpoints and outcome measures for clinical trials for products intended to treat adult and/or pediatric celiac disease and inflammatory bowel disease.
Continue ReadingAs we continue our journey toward advancing awareness and understanding of celiac disease, it is crucial that we reflect on health equity and the persistent clinical disparities within our community—so that together we can confront these factors and dismantle barriers hindering access to care and support. Health equity represents the...